drugset / Trial / NCT01996618

Study to Reduce Symptoms of Premature Beats With Ranolazine

NCT01996618

Phase 4 Unknown 72 enrolled Walter Reed National Military Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

Investigate whether ranolazine, a novel anti-anginal agent with antiarrhythmic properties, has a role in the management of symptomatic ventricular premature beats.

Timeline

Start
2014-01
Primary completion
2016-06
Completion
2016-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 1000 mg

Indications

No indication recorded.